Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CytomX Therapeutics, Inc. | Chief Financial Officer | Common Stock | 38.2K | $52.8K | $1.38 | Mar 16, 2023 | Direct |
Zymeworks Inc. | Director | Stock Option (Right to Buy) | 37K | Dec 7, 2023 | Direct | ||
Zymeworks Inc. | Director | No securities are beneficially owned | 0 | Jun 30, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ZYME | Zymeworks Inc. | Dec 7, 2023 | 1 | $0 | 4 | Dec 8, 2023 | Director |
ZYME | Zymeworks Inc. | Jun 30, 2023 | 1 | $0 | 4 | Jun 30, 2023 | Director |
ZYME | Zymeworks Inc. | Jun 30, 2023 | 0 | $0 | 3 | Jun 30, 2023 | Director |
CTMX | CytomX Therapeutics, Inc. | Mar 16, 2023 | 1 | -$3.46K | 4 | Mar 20, 2023 | Chief Financial Officer |
CTMX | CytomX Therapeutics, Inc. | Jul 19, 2022 | 2 | -$5.62K | 4 | Jul 21, 2022 | Chief Financial Officer |
CTMX | CytomX Therapeutics, Inc. | Feb 2, 2022 | 2 | $0 | 4 | Feb 4, 2022 | Chief Financial Officer |
CTMX | CytomX Therapeutics, Inc. | Oct 24, 2021 | 2 | $0 | 4 | Oct 26, 2021 | Chief Financial Officer |
CTMX | CytomX Therapeutics, Inc. | May 31, 2021 | 1 | $20.2K | 4 | Jun 8, 2021 | Chief Financial Officer |